Immunorho

Human Anti-D Immunoglobulin, the active ingredient in Immunorho, is an immunoglobulin presented as a sterile solution for intramuscular use. It prevents maternal sensitization to the Rh(D) antigen in Rh‑negative pregnant women and reduces the risk of hemolytic disease of the fetus and newborn.

GNH USA supplies Immunorho as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Immunorho, a Rh immune globulin, is used to manage Rh‑related immunologic conditions. - Rh‑negative pregnancy: prevents maternal immune sensitization to the D antigen. - Hemolytic disease of the fetus and newborn (HDFN): reduces the risk of fetal anemia and bilirubin‑induced complications. - Obstetric Rh incompatibility: provides passive immunity to avoid immune‑mediated hemolysis in the newborn.

Immunorho may cause adverse reactions following intramuscular administration.

Common Side Effects: - Injection site pain, redness or swelling. - Mild fever or chills. - Headache. - Nausea or transient dizziness.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Acute hemolysis. - Renal impairment or failure. - Serum sickness‑like reaction. - Severe hypotension or shock.

Use of Immunorho requires careful clinical assessment. - Pregnancy: administer only when the expected benefit outweighs potential risk. - Breastfeeding: evaluate risk to the infant before use. - Known hypersensitivity to human immunoglobulins: avoid administration. - IgA deficiency: monitor closely for anaphylaxis. - Concurrent large‑volume immunoglobulin therapy: consider cumulative fluid load. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunorho can interact with other agents affecting immune response or coagulation.

Major Interactions (Avoid): - Live vaccines: may reduce vaccine efficacy; avoid simultaneous administration. - IgA‑deficient plasma products: increased risk of severe allergic reaction.

Moderate Interactions (Monitor Closely): - Anticoagulants: may enhance bleeding at the injection site. - Immunosuppressants: could alter the intended passive immunity. - Additional blood products: monitor for volume overload and immune complex formation.